Zoetis Inc 's Revenue in the fiscal year 2025 $ 9,467.00 millions
Zoetis Inc 's Revenue in the fiscal year 2024 $ 9,256.00 millions
Zoetis Inc 's Revenue in the fiscal year 2023 $ 8,544.00 millions
Zoetis Inc 's Revenue in the fiscal year 2022 $ 8,080.00 millions
Zoetis Inc 's Revenue in the fiscal year 2021 $ 7,776.00 millions
ZTS Revenue second quarter 2026 Y/Y Growth Comment
Zoetis Inc reported Revenue growth of 0.33% year on year in the second quarter 2026, to $ 2,468.00 millions, this is lower than Zoetis Inc 's recent average Revenue growth of 6.25%.
Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 132 other companies have achieved higher Revenue growth. While Zoetis Inc ' s Revenue increase of 0.33% ranks overall at the positon no. 2748 in the second quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Zoetis Inc 's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
15.41 %
1.82 %
-16.52 %
(Dec 31 2012)
ZTS's II. Quarter Q/Q Revenue Comment
Zoetis Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 9.11%, to $ 2,468.00 millions, from $2,262.00 millions in the first quarter.
Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue quarter on quarter growth. While Zoetis Inc 's Revenue growth quarter on quarter, overall rank is 851.
Zoetis Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 9.11%, to $ 2,468.00 millions, from $2,262.00 millions in the first quarter.
Within Major Pharmaceutical Preparations industry 54 other companies have achieved higher Revenue quarter on quarter growth. While Zoetis Inc 's Revenue growth quarter on quarter, overall rank is 851.
Zoetis Inc 's 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Jun 30 2026)
12 Months Ending (Mar 31 2026)
12 Months Ending (Dec 31 2025)
12 Months Ending (Sep 30 2025)
12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending
$ 9,517.00
$ 9,509.00
$ 9,445.00
$ 9,375.00
$ 9,363.00
Y / Y Revenue Growth (TTM)
1.64 %
2.64 %
2.04 %
2.44 %
5.03 %
Year on Year Revenue Growth Overall
Ranking
# 2029
# 1805
# 297
# 506
# 1066
Seqeuential Revenue Change (TTM)
0.08 %
0.68 %
0.75 %
0.13 %
1.07 %
Seq. Revenue Growth (TTM) Overall
Ranking
# 2521
# 2429
# 516
# 861
# 1657
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Jun 30 2026 period, Zoetis Inc 's cumulative twelve months Revenue were $ 9,517 millions, company would post below average annual Revenue growth of 1.07% year on year, if the fiscal year would end at Jun 30 2026. A slow-down in the Zoetis Inc 's Revenue growth from the 2262% growth in Mar 31 2026.
In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1805 to 2029.
With the quarterly Revenue reported in the Jun 30 2026 period, Zoetis Inc 's cumulative twelve months Revenue were $ 9,517 millions, company would post below average annual Revenue growth of -0.42% year on year, if the fiscal year would end at Jun 30 2026. A slow-down in the Zoetis Inc 's Revenue growth from the 2262% growth in Mar 31 2026.
In the Healthcare sector 311 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1805 to 2029.
About Zoetis Inc Revenue Growth Rates (ZTS), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
0.33%